

## **Eurobio Scientific finalizes the acquisition Dutch Transplant Diagnostics firm GenDx**

**The Netherlands, UTRECHT, October 3<sup>rd</sup>, 2022**

Per today the Paris, France based Eurobio Scientific (“Eurobio”) acquires all outstanding shares of GenDx (also known as Genome Diagnostics) as was publicly announced after signing the Share Purchase Agreement on 17 August.

GenDx will continue its activities in both its Utrecht headquarters and its North American office, located in Chicago, IL. The GenDx portfolio will be continued and supported by GenDx’s existing mature sales and global distributor network. Only minor adjustments are expected to optimize the distribution channel, such that it matches with the strategy of Eurobio and its existing portfolio companies.

Co-founder of GenDx Wietse Mulder PhD, will continue as Executive Director and member of the board for an initial term of two years. Co-founder, Erik Rozemuller PhD, Senior Scientist Bioinformatics, will transition to a consultancy role to support the R&D team.

GenDx will align with the global distributor network under the umbrella of Eurobio Scientific and continue to support its customers in the field of transplant diagnostics. And importantly, proceed with R&D, operations, logistics, regulatory affairs, sales, marketing, support and educational activities.”

### ***ad tempus vitae***

This transaction is the result of an intensive project called *ad tempus vitae* (“ATV”), meaning ‘to prolong life’. This term carries double meaning. Firstly, it refers to GenDx’s offering of products and services aimed at prolonging the life of transplant patients. Secondly, it refers to prolonging the life of the Company, GenDx, by securing the legacy of the founders, which has been built over the last 18 years. The GenDx ATV project was coordinated by Jason Arnold and his London-based M&A advisory team at William Blair, with legal support from Herke van Hulst, Wouter Kok and team at Osborne & Clarke in Amsterdam. RSM provided vendor financial due diligence services to the Company.

Fostered by the *adagium* of ‘meaningful entrepreneurship’, Mulder and Rozemuller will establish the ‘GenDx foundation’, funded by proceeds of this transaction, aiming at supporting educational and R&D activities in the field of transplantation.

=====

### **About Eurobio Scientific**

Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for

research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 148 employees and three production units based in the Paris region, in Germany and in the United States, and several affiliates based in Dorking UK, Sissach Switzerland, Bünde Germany and Utrecht in The Netherlands.

Eurobio Scientific's reference shareholder is the EurobioNext holding company which brings together its two directors, Jean-Michel Carle and Denis Fortier, alongside the "Pépites et Territoires" by AXA & NextStage AM investment program, managed by NextStage AM.

For more information, please visit : [www.eurobio-scientific.com](http://www.eurobio-scientific.com)

The company is publicly listed on the Euronext Growth market in Paris

Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label.

Symbol: ALERS - ISIN Code: FR0013240934 - Reuters: ALERS.PA - Bloomberg: ALERS:FP

### **About GenDx**

Genome Diagnostics B.V., also known as GenDx, is a Dutch company specialized in molecular diagnostics, focused on development, production and sales of innovative assays and analysis software for transplant and companion diagnostics. To support GenDx's USA customers it has an office near O'Hare airport, Chicago, IL.

GenDx specializes in HLA sequencing-based typing strategies and offers reagents and software for both Sanger and NGS approaches. As one of the pioneering companies in the HLA field with Sanger approaches, GenDx started offering NGS strategies in 2013, consisting of NGSgo<sup>®</sup> reagents and the software package NGSengine<sup>®</sup> for various NGS platforms. Additionally, GenDx offers products for chimerism monitoring by qPCR and - launched recently - by NGS: NGStrack<sup>®</sup> & TRKengine<sup>®</sup>.

Recently a license was obtained from California based company Dovetail Genomics (now part of Cantata Bio) allowing GenDx to explore their hybrid capture approach enabling HLA genotyping and ultimately haplotyping of HLA genes.

Furthermore, GenDx obtained another worldwide license from Medical College Wisconsin (MCW) for their patented method to detect donor specific cell free DNA (cfDNA) in pediatric patients that have undergone a heart transplant. And, last month GenDx has signed a non-exclusive service agreement with Oxford Nanopore Technologies (Oxford Nanopore), to bring its new NGS-Turbo<sup>®</sup> product to the transplant market for high-resolution HLA typing with a turnaround time of less than four hours, enabling improved matching of solid organs in situations where time is a critical factor.

Thanks to its extensive in-house expertise, GenDx also offers custom laboratory services for basic and clinical research organizations. GenDx Education organizes dedicated HLA

sequence-based typing and chimerism monitoring training courses worldwide on a regular basis. The training courses are applicable for anyone working in tissue typing or research laboratories, blood banks, and donor registries.

GenDx is based at the Utrecht Science Park (USP), the Netherlands, and was founded in 2005 by Erik Rozemuller PhD and Wietse Mulder PhD as a spinoff of UMC Utrecht and helped by a 2002 Biopartner First Stage Grant. In 2019, Ampersand Capital Partners acquired a minority stake in the Company.

Currently, GenDx is located at USP in two opposite buildings: Alexander Numan and Androclus. In Q1-2023, GenDx will expand its footprint in A. Numan building by additionally leasing the top three floors of that building. The activities in Androclus will gradually be migrated to Numan building. Total facilities will encompass more than 3000 m<sup>2</sup>.

For further information about GenDx visit [www.GenDx.com](http://www.GenDx.com).

#### **GenDx**

Yalelaan 48  
3584 CM Utrecht  
The Netherlands  
Office: +31 30 252 3799  
E-mail: [info@gendx.com](mailto:info@gendx.com)

#### **Contact GenDx**

**Wietse Mulder PhD**, CEO  
Email: [w.mulder@gendx.com](mailto:w.mulder@gendx.com)  
Phone: +31 6 51265864  
**Maarten Penning PhD**, CTO  
Email: [m.penning@gendx.com](mailto:m.penning@gendx.com)  
Phone: +31 613367881

#### **Eurobio Scientific**

7 avenue de Scandinavie  
ZA de Courtaboeuf  
91940 Les Ulis  
France  
Office: +33 1 69 79 64 80

#### **Contact Eurobio Scientific**

**Denis Fortier**, co-CEO  
Email : [d.fortier@eurobio-scientific.com](mailto:d.fortier@eurobio-scientific.com)  
Phone : +33 1 69 79 64 80  
**Hervé Duchesne de Lamotte MBA**, CFO  
Email : [h.delamotte@eurobio-scientific.com](mailto:h.delamotte@eurobio-scientific.com)  
Phone : +33 1 69 79 64 80

*SBTEngine<sup>®</sup>, SBTExcillator<sup>®</sup>, NGSgo<sup>®</sup>, NGStrack<sup>®</sup>, NGSengine<sup>®</sup>, TRKengine<sup>®</sup>, NGS-Turbo<sup>®</sup> and GenDx are registered trademarks of Genome Diagnostics B.V.*

----